| 1 |
Sweet SC. Induction therapy in lung transplantation[J]. Transpl Int, 2013, 26(7): 696-703.
|
| 2 |
Furuya Y, Jayarajan SN, Taghavi S, et al. The impact of alemtuzumab and basiliximab induction on patient survival and time to bronchiolitis obliterans syndrome in double lung transplantation recipients[J]. Am J Transplant, 2016, 16(8): 2334-2341.
|
| 3 |
Heidt S, Hester J, Shankar S, et al. B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells[J]. Am J Transplant, 2012, 12(7): 1784-1792.
|
| 4 |
Corris PA. Induction therapy in lung transplantation? A frustrating message of persisting uncertainty[J]. Am J Transplant, 2016, 16(8): 2250-2251.
|
| 5 |
McDermott JK, Girgis RE. Individualizing immunosuppression in lung transplantation[J]. Glob Cardiol Sci Pract, 2018, 2018(1): 5.
|
| 6 |
Benzimra M, Calligaro GL, Glanville AR. Acute rejection[J]. J Thorac Dis, 2017, 9(12): 5440-5457.
|
| 7 |
Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection[J]. J Hear Lung Transplant, 2007, 26(12): 1229-1242.
|
| 8 |
Park CH, Paik HC, Haam SJ, et al. HRCT features of acute rejection in patients with bilateral lung transplantation: the usefulness of lesion distribution[J]. Transplant Proc, 2014, 46(5): 1511-1516.
|
| 9 |
Sarahrudi K, Estenne M, Corris P, et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection[J]. J Thorac Cardiovasc Surg, 2004, 127(4): 1126-1132.
|
| 10 |
Reams BD, Musselwhite LW, Zaas DW, et al. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation[J]. Am J Transplant, 2007, 7(12): 2802-2808.
|
| 11 |
Benden C, Speich R, Hofbauer GF, et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience[J]. Transplantation, 2008, 86(11): 1625-1627.
|
| 12 |
Roux A, Levine DJ, Zeevi A, et al. Banff Lung Report: Current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR)[J]. Am J Transplant, 2019, 19(1): 21-31
|
| 13 |
McManigle W, Pavlisko EN, Martinu T. Acute cellular and antibody-mediated allograft rejection[J]. Semin Respir Crit Care Med, 2013, 34(3): 320-335.
|
| 14 |
Bansal SB. Rituximab use in late antibody-mediated rejection[J]. Indian J Nephrol, 2016, 26(5): 315-316.
|
| 15 |
Witt CA, Gaut JP, Yusen RD, et al. Acute antibody-mediated rejection after lung transplantation[J]. J Hear Lung Transplant, 2013, 32(10): 1034-1040.
|
| 16 |
Yeung MY, Gabardi S, Sayegh MH. Use of polyclonal/monoclonal antibody therapies in transplantation[J]. Expert Opin Biol Ther, 2017, 17(3): 339-352.
|
| 17 |
Verleden SE, Ruttens D, Vandermeulen E, et al. Restrictive chronic lung allograft dysfunction: Where are we now？[J]. J Hear Lung Transplant, 2015, 34(5): 625-630.
|
| 18 |
Verleden GM, Raghu G, Meyer KC, et al. A new classification system for chronic lung allograft dysfunction[J]. J Hear Lung Transplant, 2014, 33(2): 127-133.
|
| 19 |
Meyer KC, Raghu G, Verleden GM, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome[J]. Eur Respir J, 2014, 44(6): 1479-1503.
|
| 20 |
Welsh CH, Wang TS, Lyu DM, et al. An international ISHLT/ATS/ERS clinical practice guideline: summary for clinicians. Bronchiolitis obliterans syndrome complicating lung transplantation[J]. Ann Am Thorac Soc, 2015, 12(1): 118-119.
|
| 21 |
Benden C, Haughton M, Leonard S, et al. Therapy options for chronic lung allograft dysfunction - bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review[J]. J Hear Lung Transplant, 2017, 36(9): 921-933.
|
| 22 |
Yung GL, Craig V. Lung transplantation and extracorporeal photopheresis: The answer to bronchiolitis obliterans？[J]. Transfus Apher Sci, 2015, 52(2): 162-166.
|
| 23 |
Verleden SE, Todd JL, Sato M, et al. Impact of CLAD phenotype on survival after lung retransplantation: a multicenter study[J]. Am J Transplant, 2015, 15(8): 2223-2230.
|
| 24 |
Vos R, Verleden SE, Verleden GM. Chronic lung allograft dysfunction: evolving practice[J]. Curr Opin Organ Transplant, 2015, 20(5): 483-491.
|